Your browser doesn't support javascript.
From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany).
Radon, Katja; Bakuli, Abhishek; Pütz, Peter; Le Gleut, Ronan; Guggenbuehl Noller, Jessica Michelle; Olbrich, Laura; Saathoff, Elmar; Garí, Mercè; Schälte, Yannik; Frahnow, Turid; Wölfel, Roman; Pritsch, Michael; Rothe, Camilla; Pletschette, Michel; Rubio-Acero, Raquel; Beyerl, Jessica; Metaxa, Dafni; Forster, Felix; Thiel, Verena; Castelletti, Noemi; Rieß, Friedrich; Diefenbach, Maximilian N; Fröschl, Günter; Bruger, Jan; Winter, Simon; Frese, Jonathan; Puchinger, Kerstin; Brand, Isabel; Kroidl, Inge; Wieser, Andreas; Hoelscher, Michael; Hasenauer, Jan; Fuchs, Christiane.
  • Radon K; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336, Munich, Germany. katja.radon@med.lmu.de.
  • Bakuli A; Center for International Health (CIH), University Hospital, LMU Munich, 80336, Munich, Germany. katja.radon@med.lmu.de.
  • Pütz P; Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337, Munich, Germany. katja.radon@med.lmu.de.
  • Le Gleut R; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Guggenbuehl Noller JM; Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany.
  • Olbrich L; Faculty of Business Administration and Economics, Bielefeld University, 33615, Bielefeld, Germany.
  • Saathoff E; Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany.
  • Garí M; Core Facility Statistical Consulting, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany.
  • Schälte Y; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Frahnow T; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Wölfel R; German Center for Infection Research (DZIF), partner site, Munich, Germany.
  • Pritsch M; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Rothe C; German Center for Infection Research (DZIF), partner site, Munich, Germany.
  • Pletschette M; Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany.
  • Rubio-Acero R; Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany.
  • Beyerl J; Center for Mathematics, Technische Universität München, 85748, Garching, Germany.
  • Metaxa D; Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany.
  • Forster F; Faculty of Business Administration and Economics, Bielefeld University, 33615, Bielefeld, Germany.
  • Thiel V; German Center for Infection Research (DZIF), partner site, Munich, Germany.
  • Castelletti N; Bundeswehr Institute of Microbiology, 80937, Munich, Germany.
  • Rieß F; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Diefenbach MN; German Center for Infection Research (DZIF), partner site, Munich, Germany.
  • Fröschl G; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Bruger J; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Winter S; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Frese J; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Puchinger K; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Brand I; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336, Munich, Germany.
  • Kroidl I; Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337, Munich, Germany.
  • Wieser A; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Hoelscher M; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Hasenauer J; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
  • Fuchs C; German Center for Infection Research (DZIF), partner site, Munich, Germany.
BMC Infect Dis ; 21(1): 925, 2021 Sep 08.
Article in English | MEDLINE | ID: covidwho-1398842
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021.

METHODS:

The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys® Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N = 2768) as well as leisure time activities (N = 1263) were collected in summer 2020.

RESULTS:

Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9-4.3%) as compared to 1.8% (95% CI 1.3-3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2020 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20-34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences.

CONCLUSION:

The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of SARS-CoV-2 sero-positive baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Observational study / Prognostic study / Risk factors Limits: Humans / Male / Infant, Newborn Country/Region as subject: Europa Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: S12879-021-06589-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Observational study / Prognostic study / Risk factors Limits: Humans / Male / Infant, Newborn Country/Region as subject: Europa Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: S12879-021-06589-4